Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects on Blood Pressure and Central Sympathetic Nerve Traffic by SGLT2-inhibition With Empagliflozin Compared to Hydrochlorothiazide in Patients With Type 2 Diabetes Mellitus

Next Previous
Trial Profile

Effects on Blood Pressure and Central Sympathetic Nerve Traffic by SGLT2-inhibition With Empagliflozin Compared to Hydrochlorothiazide in Patients With Type 2 Diabetes Mellitus

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Empagliflozin (Primary) ; Hydrochlorothiazide
  • Indications Hypertension; Type 2 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 24 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 02 Oct 2017 Planned End Date changed from 15 Aug 2019 to 15 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top